Discovery And Development

MicuRx's drug discovery platform generates best-in-class antibiotic and antifungal compounds in a rapid, cost-effective manner. Operating in Shanghai and the Bay Area, MicuRx benefits from the superior research and development expertise in the US coupled with the capital efficiencies of discovery and development and the expanding antibiotic market in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

The company focuses its discovery efforts on existing classes of underexploited drug targets, employing combinatorial chemistry, medicinal chemistry and structural activity relationship, technology to develop antibiotic and antifungal candidates with therapeutic advantages over blockbuster pharmaceuticals. The company has developed a diverse portfolio of antimicrobial compounds to treat multi-drug resistant Gram-positive, Gram-negative, fungal and other serious infections. MicuRx filed an IND and successfully completed in China for MRX-I, its antibiotic compound for the treatment of community-based drug-resistant bacterial infections. Using its proprietary discovery engine, MicuRx expects to file more Investigational New Drug (IND) application in the coming years for its novel compounds.

MRX-I: a safer oxazolidinone antibiotic to treat community-acquired MRSA

MRX-I is a next generation oral oxazolidinone antibiotic designed to treat community-acquired methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) infections. Today, physicians around the world use oxazolidinone antibiotics worldwide to treat hospital-acquired MRSA with relative success. Unfortunately, the leading antibiotic causes myelosuppression, restricting use and requiring extensive monitoring. For this reason, it is not used in a community setting.
Extensive animal studies demonstrate that MRX-I eradicates Gram-positive infections like MRSA and VRE effectively without myelosuppression. MicuRx filed an Investigational New Drug (IND) application in China, and has completed a Phase I clinical trial in 2012 for this promising antibiotic compound. Currently, MicuRx is preparing to entering Phase II clinical trial for MRX-I in both Unite States and China.
 
   
 
3916 Trust Way Hayward, CA 94545 USA     email: zyuan@micurx.com       Ph: (510) 782-2021
©MicuRx Pharmaceuticals, Inc. 2010. All rights reserved.